Paper34846705
Consensus on the secondary prevention of primary liver cancer.
Nan Y and 11 others. Hepatol Int, 2021. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Consensus on the secondary prevention of primary liver cancer. Papers, record 34846705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34846705
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Gastroenterology | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Secondary Prevention |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 35020155 | Correction to: Consensus on the secondary prevention of primary liver cancer. | https://conductscience.org/library/papers/35020155 |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18436948 | GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. | BMJ | 2008 | https://conductscience.org/library/papers/18436948 | PubMed |
| 2 | 18483053 | Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. | BMJ | 2008 | https://conductscience.org/library/papers/18483053 | PubMed |
| 3 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 4 | 25752327 | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. | Liver Int | 2015 | https://conductscience.org/library/papers/25752327 | PubMed |
| 5 | 29395269 | Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. | Lancet | 2018 | https://conductscience.org/library/papers/29395269 | PubMed |
| 6 | 28983565 | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28983565 | PubMed |
| 7 | 26566246 | Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. | Hepatology | 2016 | https://conductscience.org/library/papers/26566246 | PubMed |
| 8 | 23041539 | Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. | Clin Gastroenterol Hepatol | 2012 | https://conductscience.org/library/papers/23041539 | PubMed |
| 9 | 29624699 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. | Hepatology | 2018 | https://conductscience.org/library/papers/29624699 | PubMed |
| 10 | 16391218 | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. | JAMA | 2006 | https://conductscience.org/library/papers/16391218 | PubMed |
| 11 | 10904089 | Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10904089 | PubMed |
| 12 | 12124405 | Hepatitis B e antigen and the risk of hepatocellular carcinoma. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12124405 | PubMed |
| 13 | 18096267 | Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. | J Hepatol | 2008 | https://conductscience.org/library/papers/18096267 | PubMed |
| 14 | 30871980 | Global liver disease burdens and research trends: Analysis from a Chinese perspective. | J Hepatol | 2019 | https://conductscience.org/library/papers/30871980 | PubMed |
| 15 | 15918143 | Hepatocellular carcinoma: epidemiology, risk factors, and screening. | Semin Liver Dis | 2005 | https://conductscience.org/library/papers/15918143 | PubMed |
| 16 | 10428733 | Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. | Ann Intern Med | 1999 | https://conductscience.org/library/papers/10428733 | PubMed |
| 17 | 19395111 | Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. | J Hepatol | 2009 | https://conductscience.org/library/papers/19395111 | PubMed |
| 18 | 23094699 | Risk stratification for hepatitis B virus related hepatocellular carcinoma. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23094699 | PubMed |
| 19 | 21995442 | How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. | BMC Cancer | 2011 | https://conductscience.org/library/papers/21995442 | PubMed |
| 20 | 15066364 | A meta-analysis of alcohol consumption and the risk of 15 diseases. | Prev Med | 2004 | https://conductscience.org/library/papers/15066364 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42856947 | Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions. | Liver Res | 2026 | https://conductscience.org/library/papers/42856947 | PubMed |
| 41654824 | Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41654824 | PubMed |
| 41582564 | Intravoxel Incoherent Motion Diffusion-weighted MR Imaging for Monitoring the Therapeutic Efficacy of Interventional Photothermal Therapy with Nanoparticles in Rabbit VX2 Tumors | Curr Med Imaging | 2026 | https://conductscience.org/library/papers/41582564 | PubMed |
| 41184938 | LEAST as a novel prediction model of hepatocellular carcinoma development in patients with chronic hepatitis B: a multi-center study. | BMC Med | 2025 | https://conductscience.org/library/papers/41184938 | PubMed |
| 39959031 | Physical activity and exercise in liver cancer. | Liver Res | 2024 | https://conductscience.org/library/papers/39959031 | PubMed |
| 38966543 | Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38966543 | PubMed |
| 37568847 | Application of the Multi-Omics Liquid Biopsy Method M2P-HCC in Early Liver Cancer Screening for High-Risk Individuals with Hepatitis B-Related Liver Cancer. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/37568847 | PubMed |
| 37009320 | Prevention of malignant digestive system tumors should focus on the control of chronic inflammation. | World J Gastrointest Oncol | 2023 | https://conductscience.org/library/papers/37009320 | PubMed |
| 36924120 | The clinical management of hepatocellular carcinoma in China: Progress and challenges. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36924120 | PubMed |
| 35498180 | Evaluation of Therapeutic Effects of Computed Tomography Imaging Classification Algorithm-Based Transcatheter Arterial Chemoembolization on Primary Hepatocellular Carcinoma. | Comput Intell Neurosci | 2022 | https://conductscience.org/library/papers/35498180 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE | 1636 | PubTator's text mining | https://conductscience.org/library/genes/1636 | NCBI Gene |
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| F2 | 2147 | PubTator's text mining | https://conductscience.org/library/genes/2147 | NCBI Gene |
| GPC3 | 2719 | PubTator's text mining | https://conductscience.org/library/genes/2719 | NCBI Gene |
| SPP1 | 6696 | PubTator's text mining | https://conductscience.org/library/genes/6696 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34846705
GET https://conductscience.org/api/papers/v1/34846705/references?page=2